Reviews on Long COVID: A scope of the literature: Update July 2024

Claire Louise Khouja; Gary Austin Raine; Melissa Harden; Katy Sutcliffe; Amanda Jayne Sowden

Reviews on Long COVID: A scope of the literature: Update July 2024

Claire Louise Khouja, Gary Austin Raine, Melissa Harden, Katy Sutcliffe, Amanda Jayne Sowden

Centre for Reviews and Dissemination

Research output: Book/Report › Commissioned report

Abstract

• For this update, we identified 33 published reviews and 43 review protocols for Long COVID.
• The number of reviews (n=33) is fewer than in April 2024 (n=36), January 2024 (n=42), and October 2023 (n=46), but more than in July 2023 (n=31).
• The largest category of reviews focused on treatment or rehabilitation (13/33), whereas the prevalence of symptoms or effects (n=7, for this update) was the largest category within all previous reports.
• We identified four reviews on risk factors with or without prevalence, three on pathobiology or mechanisms, and two on prevention; the other four were on treatment with: prevalence (n=2), prevention (n=1), or risk factors (n=1).
• We identified fewer protocols (n=43) than in the previous update (April 2024, n=63) and July 2023 (n=53), but a similar number to January 2024 (n=42) and October 2023 (n=44).
• As in previous reports, the largest two categories of protocols focused on the prevalence of symptoms or effects (16/43), and treatment or rehabilitation (11/43).
• Six protocols were focused on risk factors with or without prevalence, and four were on prevention; these numbers are similar to those in previous reports. Three protocols were on experiences of Long COVID with or without prevalence, and three protocols were on pathobiology; pathobiology and treatment; and prevalence and treatment.

Original language	English
Place of Publication	London
Publisher	EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.
Commissioning body	NIHR Policy Research Programme
Number of pages	33
ISBN (Print)	978-1-911605-62-1
Publication status	Published - 9 Sept 2024

Bibliographical note

Access to Document

Review_update_July24_6th Aug-090924-LO
© Copyright 2024 Authors of the systematic reviews on the EPPI Centre website (http://eppi.ioe.ac.uk/) hold the copyright for the text of their reviews. The EPPI Centre owns the copyright for all material on the website it has developed, including the contents of the databases, manuals, and keywording and data-extraction systems. The centre and authors give permission for users of the site to display and print the contents of the site for their own non-commercial use, providing that the materials are not modified, copyright and other proprietary notices contained in the materials are retained, and the source of the material is cited clearly following the citation details provided. Otherwise, users are not permitted to duplicate, reproduce, re-publish, distribute, or store material from this website without express written permission.
Final published version, 1.42 MBLicence: CC BY-NC

Cite this

@book{ea682c27e6564d0b835d98baa31d2a95,

title = "Reviews on Long COVID: A scope of the literature: Update July 2024",

abstract = "• For this update, we identified 33 published reviews and 43 review protocols for Long COVID.• The number of reviews (n=33) is fewer than in April 2024 (n=36), January 2024 (n=42), and October 2023 (n=46), but more than in July 2023 (n=31).• The largest category of reviews focused on treatment or rehabilitation (13/33), whereas the prevalence of symptoms or effects (n=7, for this update) was the largest category within all previous reports.• We identified four reviews on risk factors with or without prevalence, three on pathobiology or mechanisms, and two on prevention; the other four were on treatment with: prevalence (n=2), prevention (n=1), or risk factors (n=1).• We identified fewer protocols (n=43) than in the previous update (April 2024, n=63) and July 2023 (n=53), but a similar number to January 2024 (n=42) and October 2023 (n=44).• As in previous reports, the largest two categories of protocols focused on the prevalence of symptoms or effects (16/43), and treatment or rehabilitation (11/43).• Six protocols were focused on risk factors with or without prevalence, and four were on prevention; these numbers are similar to those in previous reports. Three protocols were on experiences of Long COVID with or without prevalence, and three protocols were on pathobiology; pathobiology and treatment; and prevalence and treatment.",

author = "Khouja, {Claire Louise} and Raine, {Gary Austin} and Melissa Harden and Katy Sutcliffe and Sowden, {Amanda Jayne}",

year = "2024",

month = sep,

day = "9",

language = "English",

isbn = "978-1-911605-62-1",

publisher = "EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.",

}

TY - BOOK

T1 - Reviews on Long COVID: A scope of the literature

T2 - Update July 2024

AU - Khouja, Claire Louise

AU - Raine, Gary Austin

AU - Harden, Melissa

AU - Sutcliffe, Katy

AU - Sowden, Amanda Jayne

PY - 2024/9/9

Y1 - 2024/9/9

N2 - • For this update, we identified 33 published reviews and 43 review protocols for Long COVID.• The number of reviews (n=33) is fewer than in April 2024 (n=36), January 2024 (n=42), and October 2023 (n=46), but more than in July 2023 (n=31).• The largest category of reviews focused on treatment or rehabilitation (13/33), whereas the prevalence of symptoms or effects (n=7, for this update) was the largest category within all previous reports.• We identified four reviews on risk factors with or without prevalence, three on pathobiology or mechanisms, and two on prevention; the other four were on treatment with: prevalence (n=2), prevention (n=1), or risk factors (n=1).• We identified fewer protocols (n=43) than in the previous update (April 2024, n=63) and July 2023 (n=53), but a similar number to January 2024 (n=42) and October 2023 (n=44).• As in previous reports, the largest two categories of protocols focused on the prevalence of symptoms or effects (16/43), and treatment or rehabilitation (11/43).• Six protocols were focused on risk factors with or without prevalence, and four were on prevention; these numbers are similar to those in previous reports. Three protocols were on experiences of Long COVID with or without prevalence, and three protocols were on pathobiology; pathobiology and treatment; and prevalence and treatment.

AB - • For this update, we identified 33 published reviews and 43 review protocols for Long COVID.• The number of reviews (n=33) is fewer than in April 2024 (n=36), January 2024 (n=42), and October 2023 (n=46), but more than in July 2023 (n=31).• The largest category of reviews focused on treatment or rehabilitation (13/33), whereas the prevalence of symptoms or effects (n=7, for this update) was the largest category within all previous reports.• We identified four reviews on risk factors with or without prevalence, three on pathobiology or mechanisms, and two on prevention; the other four were on treatment with: prevalence (n=2), prevention (n=1), or risk factors (n=1).• We identified fewer protocols (n=43) than in the previous update (April 2024, n=63) and July 2023 (n=53), but a similar number to January 2024 (n=42) and October 2023 (n=44).• As in previous reports, the largest two categories of protocols focused on the prevalence of symptoms or effects (16/43), and treatment or rehabilitation (11/43).• Six protocols were focused on risk factors with or without prevalence, and four were on prevention; these numbers are similar to those in previous reports. Three protocols were on experiences of Long COVID with or without prevalence, and three protocols were on pathobiology; pathobiology and treatment; and prevalence and treatment.

M3 - Commissioned report

SN - 978-1-911605-62-1

BT - Reviews on Long COVID: A scope of the literature

PB - EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.

CY - London

ER -